Orgenesis Inc

Orgenesis Inc. is a privately held biotechnology company headquartered in Germantown, Maryland. Founded in 2012, the company employs 83 people and generates an annual revenue of $50 million. Orgenesis focuses on developing and commercializing decentralized cell and gene therapies (CGTs). They aim to make these innovative treatments more affordable and accessible to patients worldwide through their POCare Network, a collaboration between academia, hospitals, and industry partners. The company's POCare Services business unit is responsible for establishing and managing decentralized POCare Centers and proprietary OMPULs (Off-the-Shelf Platform for Universal Cell Manufacturing). Orgenesis distinguishes itself by its commitment to advancing CGTs to market through strategic partnerships. Their approach prioritizes a rapid, globally harmonized pathway for these therapies to reach patients efficiently and cost-effectively. The company's decentralized production model seeks to lower costs and increase accessibility to patients. For more information about Orgenesis and its offerings, please visit their website at orgenesis.com.

Orgenesis Inc. is a biotechnology company specializing in the development and commercialization of cell and gene therapies (CGTs). The company's primary focus is on utilizing its Point of Care (POCare) Platform. Orgenesis Inc. is located in Germantown, MD 20876, USA, at 20271 Goldenrod Lane. Orgenesis Inc. operates within the healthcare, biotechnology, and pharmaceuticals industries. The company aims to make advanced therapies more affordable and accessible. It achieves this by decentralizing manufacturing processes and enabling local production of cell and gene therapies. The company's POCare Platform is central to its operations. This platform supports the development and commercialization of cell and gene therapies. Orgenesis Inc. offers a decentralized manufacturing platform. This platform provides cost-effective and scalable manufacturing capacities. The company also focuses on global harmonization and standardization within its processes. Orgenesis Inc. has a shortened implementation time, reducing it from 18-24 months to 3-6 months. Orgenesis Inc. targets the healthcare, biotechnology, and pharmaceutical industries. The company's competitive advantages include its decentralized manufacturing platform, which offers cost-effective and scalable manufacturing capacities. Furthermore, Orgenesis Inc. emphasizes global harmonization and standardization. The company also boasts a shortened implementation time. Orgenesis Inc. is led by Chief Executive Officer Vered Caplan, Chief Financial Officer Victor Miller, and Medical Director Heiko von der Leyen. The company's values include innovation, quality control, regulatory compliance, global quality harmonization, and a standardized training program. For inquiries, the company can be contacted via email at [email protected].